Relay Therapeutics (RLAY) Price Target Raised to $29 by H.C. Wainwright

H.C. Wainwright has raised its price target for Relay Therapeutics (RLAY) to $29. This figure marks an increase from a previously lower estimate, reflecting the firm's confidence in Relay's potential growth. The updated target suggests positive sentiment surrounding the company's future performance, which could influence investor perception and trading behavior. Investors should consider how this price target adjustment might affect market valuations for Relay Therapeutics.